Skip to content

Research at St Andrews

Identifiction of molelcular apocrine breast tumours by microarray anaylsis

Research output: Contribution to journalArticlepeer-review

DOI

Author(s)

P Farmer, H Bonnefoi, V Becette, M Tubiana-Hulin, P Fumoleau, D Larsimont, G MacGrogan, J Bergh, D Cameron, D Goldstein, S Duss, A-L Nicoulaz, C Brisken, M Fiche, M Delorenzi, Richard Derek Iggo

School/Research organisations

Abstract

Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of the oestrogen receptor alpha gene (ER). We report here the identification of a group of breast tumours with increased androgen signalling and a 'molecular apocrine' gene expression profile. Tumour samples from 49 patients with large operable or locally advanced breast cancers were tested on Affymetrix U133A gene expression microarrays. Principal components analysis and hierarchical clustering split the tumours into three groups: basal, luminal and a group we call molecular apocrine. All of the molecular apocrine tumours have strong apocrine features on histological examination (P=0.0002). The molecular apocrine group is androgen receptor (AR) positive and contains all of the ER-negative tumours outside the basal group. Kolmogorov–Smirnov testing indicates that oestrogen signalling is most active in the luminal group, and androgen signalling is most active in the molecular apocrine group. ERBB2 amplification is commoner in the molecular apocrine than the other groups. Genes that best split the three groups were identified by Wilcoxon test. Correlation of the average expression profile of these genes in our data with the expression profile of individual tumours in four published breast cancer studies suggest that molecular apocrine tumours represent 8–14% of tumours in these studies. Our data show that it is possible with microarray data to divide mammary tumour cells into three groups based on steroid receptor activity: luminal (ER+ AR+), basal (ER- AR-) and molecular apocrine (ER- AR+).
Close

Details

Original languageEnglish
Pages (from-to)4660-4671
JournalOncogene
Volume24
Issue number29
DOIs
Publication statusPublished - Jul 2005

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by journal

  1. Oncogene (Journal)

    Paul Andrew Reynolds (Reviewer)

    2014 → …

    Activity: Publication peer-review and editorial work typesPeer review of manuscripts

Related by journal

  1. KIBRA Exhibits MST-independent Functional Regulation of the Hippo Signaling Pathway in Mammals

    Moleirinho, S., Chang, N., Sims, A., Tilston-Lunel, A. M., Angus, L., Steele, A., Boswell, V., Barnett, S., Ormandy, C., Faratian, D., Gunn-Moore, F. J. & Reynolds, P. A., 2013, In: Oncogene. 32, 14, p. 1821-1830 10 p.

    Research output: Contribution to journalArticlepeer-review

  2. Willin/FRMD6 Expression Activates the Hippo Signaling Pathway Kinases in Mammals and Antagonizes Oncogenic YAP

    Angus, L., Moleirinho, S., Herron, L. R., Sinha, A., Zhang, X., Niestrata, M., Dholakia, K., Prystowsky, M., Harvey, K., Reynolds, P. A. & Gunn-Moore, F. J., 2012, In: Oncogene. 31, 2, p. 238-250 13 p.

    Research output: Contribution to journalArticlepeer-review

  3. E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells

    Prost, S., Lu, P., Caldwell, H. & Harrison, D., May 2007, In: Oncogene. 26, 24, p. 3572-3581 10 p.

    Research output: Contribution to journalArticlepeer-review

  4. Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia

    Suraweera, N., Meijne, E., Moody, J., Carvajal-Carmona, L., Yoshida, K., Pollard, P., Fitzgibbon, J., Riches, A. C., Van Laar, T., Huiskamp, R., Rowan, A., Tomlinson, I. P. M. & Silver, A., 19 May 2005, In: Oncogene. 24, p. 3678-3683 6 p.

    Research output: Contribution to journalArticlepeer-review

ID: 349085

Top